The binding to K-RasG13D/PDE6δ reduces the activation of Ras proteins, making these compounds good candidates for targeted therapies against breast cancer, particularly in TNBC or in patients that present resistances to conventional therapies, in which dysregulation in the Ras pathway generally occurs and plays a central role in tumorigenesis (14). Here, PDE6D is linked to breast cancer.